Merit Medical Announces Multiple Regulatory Approvals

Merit Medical Announces Multiple Regulatory Approvals

SOUTH JORDAN, Utah, July 1, 2013 (GLOBE NEWSWIRE) -- Merit Medical Systems,
Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary
disposable devices used primarily in cardiology, radiology and endoscopy,
today announced that it has received multiple regulatory approvals from
various regulatory bodies.

The basixTOUCH™, Merit's most advanced high-pressure inflation device, has
received 510(k) clearance from the FDA. The "Touch," which attained the CE
mark early in the second quarter of 2013, has had substantial success in the
first two months of its European release.The "Touch" eliminates the need to
use multiple inflation devices in some advanced interventional cases because
of its high pressure range.The Company also received initial acceptance of a
number of claims from its U.S. patent application.

"We believe the introduction of the basixTOUCH clearly places Merit in the
worldwide leadership position for inflation devices which are used in numerous
interventional and peripheral procedures," said Fred P. Lampropoulos, Merit's
Chairman and Chief Executive Officer."The features of this device can also be
applied to other inflation products such as the Blue Diamond™ digital
inflation system.This device and its derivatives have the potential, when
combined with other devices such as our hemostasis valves, to become the
largest single revenue producing product in Merit's history."

Merit also announced that it has been notified by its embolic business partner
in Japan, Nippon Kayaku, that it has received approval from Japan's
Pharmaceuticals and Medical Devices Agency (PMDA) for Embosphere® and
HepaSphere™ Microspheres as medical devices for the purpose of arterial
embolization in patients with hypervascular tumors and arteriovenous
malformations.

"We are pleased with the substantial efforts of our partner to bring this
highly needed product to the people of Japan," Lampropoulos said."Initial
shipments are scheduled to begin in the third quarter of 2013."

Merit also announced that it has received 510(k) clearance for its Bearing™
nsPVA Embolization Particles.

"This embolic product, which was developed in our French facility, adds an
additional product to our portfolio to complement our Embosphere, HepaSphere
and QuadraSphere™ product offering," Lampropoulos said."The Bearing nsPVA has
broad appeal worldwide and has also received the CE mark."

Finally, the China Food and Drug Administration (CFDA) has renewed its
clearance of Merit's Embosphere product line.

"We believe the efforts of our regulatory staff and business partners
worldwide will enhance our business prospects and growth moving forward,"
Lampropoulos said.

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development,
manufacture and distribution of proprietary disposable medical devices used in
interventional and diagnostic procedures, particularly in cardiology,
radiology and endoscopy. Merit serves client hospitals worldwide with a
domestic and international sales force totaling approximately 200 individuals.
Merit employs approximately 2,750 people worldwide with facilities in Salt
Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Virginia;
Malvern, Pennsylvania; Maastricht and Venlo, The Netherlands; Paris, France;
Galway, Ireland; Beijing, China; Copenhagen, Denmark; and Rockland,
Massachusetts.

Statements contained in this release which are not purely historical,
including, without limitation, statements regarding Merit's forecasted
revenues, net income, financial results or anticipated acquisitions, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks and uncertainties such
as those described in Merit's Annual Report on Form 10-K for the year ended
December 31, 2012. Such risks and uncertainties include risks relating to
Merit's potential inability to successfully manage growth through
acquisitions, including the inability to commercialize technology acquired
through recent, proposed or future transactions;product recalls and product
liability claims; expenditures relating to research, development, testing and
regulatory approval or clearance of Merit's products and risks that such
products may not be developed successfully or approved for commercial use;
greater governmental scrutiny and regulation of the medical device industry;
reforms to the 510(k) process administered by the U.S. Food and Drug
Administration; compliance with governmental regulations and administrative
procedures; potential restrictions on Merit's liquidity or its ability to
operate its business by its current debt agreements; possible infringement of
Merit's technology or the assertion that Merit's technology infringes the
rights of other parties; the potential of fines, penalties, or other adverse
consequences if Merit's employees or agents violate the U.S. Foreign Corrupt
Practices Act or other laws and regulations; laws targeting fraud and abuse in
the healthcare industry; potential for significant adverse changes in, or
failure to comply with, governing regulations; the effect of changes in tax
laws and regulations in the United States or other countries; increases in the
price of commodity components; negative changes in economic and industry
conditions in the United States and other countries; termination or
interruption of relationships with Merit's suppliers, or failure of such
suppliers to perform; fluctuations in Euro and GBP exchange rates; Merit's
need to generate sufficient cash flow to fund its debt obligations, capital
expenditures, and ongoing operations; concentration of Merit's revenues among
a few products and procedures; development of new products and technology that
could render Merit's existing products obsolete; market acceptance of new
products; volatility in the market price of Merit's common stock; modification
or limitation of governmental or private insurance reimbursement policies;
changes in health care markets related to health care reform initiatives;
failure to comply with applicable environmental laws; changes in key
personnel; work stoppage or transportation risks; uncertainties associated
with potential healthcare policy changes which may have a material adverse
effect on Merit; introduction of products in a timely fashion; price and
product competition; availability of labor and materials; cost increases;
fluctuations in and obsolescence of inventory; and other factors referred to
in Merit's Annual Report on Form 10-K for the year ended December 31, 2012 and
other materials filed with the Securities and Exchange Commission. All
subsequent forward-looking statements attributable to Merit or persons acting
on its behalf are expressly qualified in their entirety by these cautionary
statements. Actual results will differ, and may differ materially, from
anticipated results. Financial estimates are subject to change and are not
intended to be relied upon as predictions of future operating results, and
Merit assumes no obligation to update or disclose revisions to those
estimates.

CONTACT: Anne-Marie Wright
         Vice President, Corporate Communications
         (801) 208-4167
         e-mail: awright@merit.com
         Fax: (801) 253-1688

company logo
 
Press spacebar to pause and continue. Press esc to stop.